Flemming Ørnskov
Dieser Inhalt ist noch nicht in deiner Sprache verfügbar.
Flemming Ørnskov, M.D., MPH is Chief Executive Officer of Galderma. In the Botulinum Index graph, he represents the executive leadership node for Galderma’s transition into a public dermatology company with a major injectable-aesthetics portfolio.
His role is relevant to botulinum toxin coverage because Galderma connects two different toxin relationships: aesthetic commercialization of Dysport in licensed markets and development of relabotulinumtoxinA, marketed internationally as Relfydess where approved.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Galderma |
| Current role | Chief Executive Officer |
| Joined Galderma | October 2019 |
| Relevant company node | Galderma |
| Relevant brand nodes | Dysport and Relfydess / relabotulinumtoxinA |
| Official profile | Galderma: Flemming Ørnskov, M.D., MPH 🔗 |
Career Notes
Section titled “Career Notes”- Ørnskov joined Galderma as Chief Executive Officer in October 2019.
- Before Galderma, he served as Chief Executive Officer of Shire plc from 2013 to 2019.
- His earlier career included leadership roles at Bayer, Novartis, and Merck.
- Galderma identifies him as non-executive Chairman of Waters Corporation.
- He trained as a Doctor of Medicine at the University of Copenhagen Medical School and earned an MPH from Harvard University School of Public Health and an MBA from INSEAD.
Galderma, Dysport, and Relfydess Context
Section titled “Galderma, Dysport, and Relfydess Context”Ørnskov’s page is most useful as a company-strategy anchor rather than as a product-origin claim. Galderma commercializes Dysport-family aesthetic products in licensed territories, while Ipsen remains the core Dysport product-origin and manufacturing reference point. Relfydess is different: it is Galderma’s relabotulinumtoxinA product in approved international markets.
That distinction matters because Galderma’s toxin role is not a single manufacturer label. The company is both a commercialization partner for an established Ipsen-origin product family and the developer of a separate relabotulinumtoxinA product with its own regulatory path.
Activity and Public Context
Section titled “Activity and Public Context”Galderma’s 2025 annual report presents Ørnskov as Chief Executive Officer and frames 2025 as a year of growth after the company’s 2024 listing on the SIX Swiss Exchange. The same annual report identifies Relfydess as part of Galderma’s injectable-aesthetics innovation activity in markets where the product had received regulatory approvals.
For U.S. interpretation, Relfydess should still be treated separately from Galderma’s approved and commercialized products. FDA acceptance of a BLA resubmission is a review milestone, not approval, and reported complete response letters should not be rewritten as evidence of clinical inferiority or superiority.